Form 4: AEON Biopharma Executive Jennifer Sy Receives Stock Options and Restricted Stock Units

Jennifer Sy, Principal Accounting Officer of AEON Biopharma, was granted stock options and restricted stock units on August 31, 2024.

Summary

• Jennifer Sy, the Principal Accounting Officer of AEON Biopharma, received an award of 18,010 Class A Common Stock restricted stock units on August 31, 2024.
• These restricted stock units will vest in full on the second anniversary of the grant date, contingent upon Ms. Sy's continued service.
• Ms. Sy also received an award of 48,063 stock options on August 31, 2024, with an exercise price of $0.83.
• These options vest in substantially equal monthly installments over the eighteen months following the grant date, also subject to continued service.
• The stock options expire on August 30, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of equity compensation is generally viewed favorably as it aligns management's interests with shareholders, but the document itself is simply a report of the transaction.

Positives

• The grant of stock options and restricted stock units aligns Ms. Sy's interests with those of the shareholders.
• The vesting schedules incentivize continued service and contribution to the company's success.

Risks

• The value of the stock options and restricted stock units is dependent on the future performance of AEON Biopharma's stock.
• If Ms. Sy's employment terminates before the vesting dates, she will forfeit the unvested awards.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of continued service and contribution from the executive.

Industry Context

Granting stock options and restricted stock units is a common practice in the biopharmaceutical industry to attract, retain, and incentivize key personnel.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to increase shareholder value.
• Employees may see the grants as a positive sign of the company's commitment to its employees.

Key Dates

Keywords

stock options, restricted stock units, Form 4, beneficial ownership, AEON Biopharma, Jennifer Sy, equity compensation